- Home
- CTRN vs SCTX Comparison
CTRN vs SCTX Comparison
Compare CTRN & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTRN | SCTX |
|---|---|---|
| Founded | 1946 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 559.1M | 536.5M |
| IPO Year | 2005 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CTRN | SCTX |
|---|---|---|
| Price | $71.16 | $28.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $52.00 | N/A |
| AVG Volume (30 Days) | 138.8K | ★ 206.4K |
| Earning Date | 06-02-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.14 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $819,962,000.00 | N/A |
| Revenue This Year | $8.81 | N/A |
| Revenue Next Year | $8.35 | N/A |
| P/E Ratio | $75.16 | ★ N/A |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $29.60 | $17.31 |
| 52 Week High | $77.91 | $39.60 |
Technical Indicators
Market Signals| Indicator | CTRN | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 55.63 |
| Support Level | $65.38 | $27.20 |
| Resistance Level | $76.49 | $39.60 |
| Average True Range (ATR) | 3.13 | 4.77 |
| MACD | -0.90 | -0.15 |
| Stochastic Oscillator | 31.17 | 51.05 |
Price Performance
Historical ComparisonAbout CTRN Citi Trends Inc.
Citi Trends Inc is a differentiated off-price value retailer known for trendy fashions, great brands and amazing prices. It is the off-price retailer specifically focused on Black customers, delivering the styles, brands, and trends at amazing prices that resonate with its primary and secondary customers. Its product offering is Women's, Men's and Children's apparel, family footwear, accessories and products for the home, with a three-tiered mix of product. At the opening price point, the company offers value-focused basics for its budget-conscious customers.
About SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.